Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Recent Advances in Immunotherapy of Cancer
share announcement

Recent Advances in Immunotherapy of Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 25 August 2025 | Viewed by 1323

Special Issue Editors

Dr. Jessica Chacon

E-Mail Website
Guest Editor
Texas Tech University Health Sciences Center, El Paso, TX, USA
Interests: tumor immunology; immunotherapy; adoptive cell therapy; melanoma; tumor-infiltrating lymphocytes
Special Issues, Collections and Topics in MDPI journals
Dr. Shrikanth Gadad

E-Mail Website
Guest Editor
Texas Tech University Health Sciences Center, El Paso, TX, USA
Interests: cancer; metastasis; DNA; gene regulation; transcription; epigenetics; genome biology

Special Issue Information

Dear Colleagues,

Cancer immunotherapy has transformed cancer treatment by leveraging the immune system to identify and eradicate tumors. Advances such as immune checkpoint inhibitors, CAR T-cell therapies, and tumor-infiltrating lymphocyte therapies have significantly enhanced patient outcomes. However, challenges such as treatment resistance, patient heterogeneity, and the increasing incidence of immune-related adverse events (irAEs) continue to pose significant obstacles. A comprehensive understanding and management of irAEs, which can range from mild to life-threatening, has become essential to ensure the safe and effective application of immunotherapies.

Incorporating artificial intelligence (AI) has transformative potential in addressing the challenges associated with cancer treatment. AI-driven approaches enhance precision medicine by optimizing patient selection, identifying biomarkers for treatment response and toxicity, and elucidating the complex dynamics of tumor–immune interactions. Additionally, AI facilitates early detection and management of immune-related adverse events (irAEs) by predicting at-risk patients and personalizing interventions. Furthermore, AI accelerates drug discovery, designs innovative combination therapies, and improves the efficiency of clinical trials.

This Special Issue aims to highlight advancements in cancer immunotherapy, the management of irAEs, and the integration of AI to refine and personalize therapeutic strategies. We invite authors to submit papers on a variety of approaches to propel the field of immunotherapy toward safer, more effective, and tailored cancer treatments.

Dr. Jessica Chacon
Dr. Shrikanth Gadad
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • immunology
  • cancer
  • oncology
  • tumor immune microenvironment
  • artificial intelligence
  • immune-related adverse events

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

17 pages, 3339 KiB  
Systematic Review
Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological Outcomes
by Nur Olgun, Mehmet Emin Arayici, Deniz Kızmazoglu and Refik Emre Cecen
J. Clin. Med. 2025, 14(3), 934; https://doi.org/10.3390/jcm14030934 - 31 Jan 2025
Viewed by 1134
Abstract
Background: Neuroblastoma is a highly aggressive pediatric cancer, particularly in children with refractory or relapsed disease, where survival outcomes remain poor despite advancements in treatment. Combining anti-GD2 antibodies, such as dinutixumab beta, dinutixumab, and naxitanab, with conventional chemotherapy has emerged as a promising [...] Read more.
Background: Neuroblastoma is a highly aggressive pediatric cancer, particularly in children with refractory or relapsed disease, where survival outcomes remain poor despite advancements in treatment. Combining anti-GD2 antibodies, such as dinutixumab beta, dinutixumab, and naxitanab, with conventional chemotherapy has emerged as a promising approach to improve clinical outcomes in this high-risk population. This chemo-immunotherapy regimen meta-analysis aimed to investigate the efficacy of these combination regimens by analyzing objective response rate (ORR), overall survival (OS), and event-free survival (EFS) outcomes across multiple studies. Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed, Web of Science, and Scopus databases were searched, yielding studies comprising the related reports. Both randomized controlled trials and non-randomized studies were included. The primary outcome of interest was ORR, and the secondary outcome of interest was EFS. A random-effects model using the DerSimonian–Laird method and Knapp–Hartung–Sidik–Jonkman adjustments was employed to pool effect sizes, and heterogeneity was assessed using I2 statistics. Results: A total of ten reports from eight studies were deemed eligible and included in the meta-analysis. The pooled ORR across the studies was 0.45 (95% CI: 0.35–0.54, p < 0.001), indicating that approximately 45% of patients showed a favorable treatment response, with moderate heterogeneity (I2 = 52.78%). The pooled analysis showed an OS of 75% (95% CI: 53–96, p < 0.001), and the pooled EFS effect size was 0.59 (95% CI: 0.45–0.73, p < 0.001), despite substantial heterogeneity (I2 = 60.54%). Conclusions: anti-GD2 antibodies combined with conventional chemotherapy may significantly improve response rates and event-free survival in children with refractory or relapsed neuroblastoma. Future research should focus on identifying predictive biomarkers to tailor therapies to individual patients, enhancing both efficacy and safety in this vulnerable population. Full article
(This article belongs to the Special Issue Recent Advances in Immunotherapy of Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop